These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15550140)

  • 1. Elevated MIA levels in the serum of pregnant women and of children.
    Bosserhoff AK; Küster H; Hein R
    Clin Exp Dermatol; 2004 Nov; 29(6):628-9. PubMed ID: 15550140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
    Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
    Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
    Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
    Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
    Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the determination of serum markers in patients with malignant melanoma.
    Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
    Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
    Klimek VM; Williams L; Chapman PB
    Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma.
    Guba M; Steinbauer M; Ruhland V; Schütz A; Geissler EK; Anthuber M; Vogt T; Bosserhoff A; Jauch KW
    Oncol Rep; 2002; 9(5):981-4. PubMed ID: 12168059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum markers in skin melanoma--preliminary study.
    Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
    Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
    Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
    Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
    Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
    Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers].
    Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520
    [No Abstract]   [Full Text] [Related]  

  • 14. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients.
    Klingenstein A; Haritoglou I; Schaumberger MM; Nentwich MM; Hein R; Schaller UC
    Melanoma Res; 2011 Aug; 21(4):352-6. PubMed ID: 21540751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
    Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
    Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy.
    Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD
    Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
    Vandooren B; Cantaert T; van Lierop MJ; Bos E; De Rycke L; Veys EM; De Keyser F; Bresnihan B; Luyten FP; Verdonk PC; Tak PP; Boots AH; Baeten D
    Ann Rheum Dis; 2009 Jun; 68(6):1044-50. PubMed ID: 18633128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
    Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
    Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer.
    Aung PP; Oue N; Mitani Y; Nakayama H; Yoshida K; Noguchi T; Bosserhoff AK; Yasui W
    Oncogene; 2006 Apr; 25(17):2546-57. PubMed ID: 16331256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.
    Krähn G; Kaskel P; Sander S; Waizenhöfer PJ; Wortmann S; Leiter U; Peter RU
    Anticancer Res; 2001; 21(2B):1311-6. PubMed ID: 11396205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.